Cancer clinical trials in the region Nouvelle-Aquitaine

393 currently recruiting clinical trials
Region Nouvelle-Aquitaine
Phase 2 / Phase 3 Head and neck cancer #NCT06788990 #2024-519654-37-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required HPV statuses
HPV Negative
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
12 recruiting sites
Bicara Therapeutics
Phase 2 / Phase 3 Head and neck cancer #NCT04534205 #2020-001400-41
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required P16 statuses
P16 Positive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
6 recruiting sites
BioNTech SE
Phase 2 / Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07106762 #2025-522400-24-00
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Antibody Drug Conjugates (ADC)
10 recruiting sites
Bristol-Myers Squibb
Phase 2 / Phase 3 Lung cancer #NCT05255302 #2024-515945-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR HER2 NTRK-1/2/3 RET ROS-1 Other mutation
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy
12 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 2 Lung cancer #NCT05742607
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR
Excluded previous treatments at localized stage
Immunotherapy Targeted therapy
6 recruiting sites
Innate Pharma
Phase 2 Lymphoma Brain tumors / Central nervous system tumors #NCT03328078 #2024-513312-95-00
Required histologic types
B cell lymphoma Other primary CNS tumor
Required histologic sub types
Primary cerebral lymphoma Primary CNS lymphoma
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Curis, Inc.
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT05503797 #2024-513578-23-00
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRAF
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
HRAS KRAS G12C KRAS non G12C NRAS
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT05503797 #2024-513578-23-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRAF
Required number of previous lines of therapy
1 2 3 or more
Excluded genetic anomalies
HRAS KRAS G12C KRAS non G12C NRAS
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT05503797 #2024-513578-23-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRAF
Required number of previous lines of therapy
1 2 3 or more
Excluded genetic anomalies
HRAS KRAS G12C KRAS non G12C NRAS
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics
Phase 2 Chronic myeloid leukemia (CML) #NCT06514534 #2024-516049-38-00
Required disease stage
Chronic phase Accelerated phase
Required genetic anomalies
T315I
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
ATP pocket inhibitor
Excluded previous treatments
Systemic Treatment-Naive Allosteric inhibitor
7 recruiting sites
Novartis